polatuzumab vedotin,glofitamab
roche
['glofitamab', 'dlbcl', 'lymsm', 'thanks', 'pola']
 presented the preliminary results from our aussie iit of #glofitamab in combination with rchp-pola or rchop as first treatment in high risk younger patients with #dlbcl #eha2023 #lymsm thanks to our sites and 
Haem/onc @Haem_pmcc_rmh in Melbourne. #Lymphoma Lead #CART Early phase trials. Lymphoma co-Chair @ALLGtrials Views are my own. #lymsm